Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
TREND Study Group
Department of Clinical Medicine
89
Citations (Scopus)
10
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ranibizumab
100%
Neovascular Age-related Macular Degeneration (nAMD)
100%
Treatment Group
33%
Visual Acuity
22%
Central Subfield Thickness
22%
Baseline Characteristics
11%
Adverse Events
11%
Age 50
11%
Patient-completed
11%
Best-corrected Visual Acuity
11%
Interventional Study
11%
Well-balancing
11%
Treatment Safety
11%
Non-inferiority
11%
Change from Baseline
11%
Least Mean Square
11%
Safety Signal
11%
Treatment Exposure
11%
Nave
11%
Letter to the
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ranibizumab
100%
Wet Macular Degeneration
100%
Treatment Group
50%
Adverse Event
16%